Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine (CC-486) in AML and MDS Post-Transplant
NCT01835587Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of CC-486 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Oct 2013; status: completed.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01835587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835587.